Business
Zio® by iRhythm Shown to Prevent Hospital Admissions, Aid in Early Detection of AF
New clinical research presented at ACC.22 shows that the Zio service is a viable solution for the early detection of silent atrial fibrillationAdditional data
About this update from Irhythm Holdings, Inc.
[{"type":"text","content":"New clinical research presented at ACC.22 shows that the Zio service is a viable solution for the early detection of silent atrial fibrillationAdditional data shows that Zio AT can positively impact hospital resources – saving one healthcare system 136 inpatient hospitalization days SAN FRANCISCO, April 03, 2022 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare solutions company focused on the advancement of cardiac care, announces the results of three clinical research studies presented at The American College of Cardiology’s 71st Annual Scientific Session & Expo (ACC.22). The new clinical evidence: Further validates the Zio service as a viable solution for the early detection of atrial fibrillation (AF),1 helping undiagnosed populations effectively seek treatment before more serious problems can occur.Shows that the Zio service can positively impact hospital resources2 – a crucial benefit during the continued COVID-19 pandemic.Supports the need for monitoring post-TAVR discharge in high-risk patient populations.3 “As the healthcare system continues to progress towards value-based medicine, we recognize that providers are increasingly challenged to improve clinical outcomes for patients while controlling costs,” said Dietra Jones, Executive Vice President, Clinical Operations at iRhythm. “We are excited that these new data continue to demonstrate that Zio’s clinical accuracy is beneficial in directing patient care across a variety of settings, while improving clinical workflows and hospital capacity. We are also particularly encouraged to see further evidence of Zio’s ability to support early detection and diagnosis of AF in moderate-risk populations.” The Syncope study, titled “Syncope Pathway Using Live Ambulatory Monitoring Streamlines ER Patient Disposition,” found that Zio AT was able to monitor and aid in diagnosis of qualified syncope patient candidates in an outpatient setting. Implementation of Zio AT allowed health systems to safely monitor patients upon discharge, avoiding a potential 24-48 hour hospital stay. Additionally, 8.2% of patients had an arrhythmia event triggering an MD notification. Nearly half (46%) of these occurred after 48 hours (longer than atypical inpatient stay) – demonstrating the importance of 14-day monitoring with Zio AT. Finally, it was concluded that ...